ACE inhibitor spirapril effects on circadian blood pressure profile, quality of life, and psychological status in patients with Stage I-II arterial hypertension

Aim. To compare spirapril and amlodipine effects on circadian blood pressure (BP) profile, quality of life (QoL), and psychological status (PS) in patients with arterial hypertension (AH).

Material and methods. This open, randomized, comparative crossover study (spirapril and amlodipine courses lasting for 4 weeks each) included 24 patients with Stage I-II AH (mean age 54,2 10,5 years; mean AH duration 12,3 10,2 years). After 7 days of no antihypertensive therapy, the participants were randomly assigned either spirapril (6 mg/d) or amlodipine (5 mg/d). In case of inadequate effectiveness, hydrochlorothiazide (25 mg) was added and/or amlodipine dose was increased to 10 mg/d; spirapril dose was unchanged. Twenty-four BP monitoring (BPM), PS and QoL assessment (MMPI, Marburg University Questionnaire) were performed. Statistical analysis was performed in SAS 6.12.

Results. Mean BP level was achieved for both medications; individual target BP levels were achieved in 17 patients receiving spirapril and 18 participants receiving amlodipine. No significant difference was observed for main 24-hour BPM parameters. Spirapril was more effective in reducing nighttime BP. Effect uniformity was similar for both agents: systolic/diastolic BP smoothness index was 0,55/0,45 (р 0,05) for spirapril and 0,65/0,56 (р 0,05) for amlodipine. Both medications did not affect QoL or PS in AH patients. Spirapril also improved socialisation, self-control, optimism, and general energy level.

Conclusion. Spirapril is a highly effective antihypertensive medication, improving not only circadian BP profile, but also PS parameters among AH patients.

1. Элиот Г.Л. Применение ингибитора ангиотензин-превращающего фермента спираприла при хронической почечной недостаточности, гипертонии и сахарном диабете. Тер архив 2000; 10: 2-6.

2. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor. A guide to selection. Drugs 1995; 49: 516-35.

3. Guitard C, Alvisi V, Maibach E, et al. Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to-severe essential hypertension. Blood Pressure 1994 (Suppl. 2): 81-7.

4. Guitard C, Lohmann FW, Alfiero R, et al. Comparison of efficacy of spirapril and enalapril in control of mild-to-moderate hypertension. Cardiovasc Drugs Ther 1997; 11(3): 449-57.

5. Widimsky J, Kremer H-J, Jerie P, Uhlir O, for the CASSIS investigators. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicenter trial in patients with congestive heart failure. Eur J Clin Pharmacol 1995; 49: 95-102.

6. Леонова М.В., Демидова М.А., Тарасов А.В., Белоусов Ю.Б. Опыт применения спираприла и его эффекты у больных с артериальнойгипертонией. РКЖ 2006; 1(57): 40-3.

7. Леонова М.В., Демидова М.А., Тарасов А.В., Белоусов Ю.Б. Гипотензивная,органопротективная и метаболическаяэффективность спираприла у больных артериальной гипертензией. РФК 2005; 2: 4-8.

8. Siegrist J, Junge A. Conceptual and methodological problems in research on the quality of life in clinical medicine. Soc Sci Med 1989; 29(3): 463-8.

9. Metelitsa VI, Douda SG, Ostrovskaya TP, et al. Long-term monotherapy with antihypertensives and quality of life in patients with mild to moderate arterial hypertension: a multicentre study. J Drug Dev Clin Pract 1996; 8(2): 61-76.

10. Зайцев В.П. Вариант психологического тестаMini-Mult.Психолог ж 1981; 2(3): 118-23.

11. Zuther P, Witte K, Lemmer B. АВРМ-FIT and CV-SORT: an Easy-to-use software package for detailed analysis of data from ambulatory blood pressure monitoring. Blood Press Monit 1996; 1: 347-54.

12. SAS User`s Guide: Statistics Version 5 Edition. Cary NC:SAS Institute Inc. 1985. 956 pp.

13. Rizzoni D, Castellano M, Muiesan ML, et al. Beyond trough: peak ratio: a new index of the smoothness of the antihypertensive effect of a drug. High Blood Press 1997; 6: 110-5.

14. Verberk WJ, Thien T, Kroon AA, et al. Prevalence and persistence of masked hypertension in treated hypertensive patients. Am J Hypertens 2007; 20(12): 1266-7.

15. Горбунов В.М. Рациональное использование суточного мониторирования артериального давления для оценки эффективности антигипертензивной терапии. Автореф дисс докт мед наук. Москва2003.

16. Шальнова С.А., Марцевич С.Ю., Деев А.Д. и др. Сравнительное изучениеэффективности спираприла (квадроприл) и амлодипина. Результаты рандомизированного исследования у больных мягкой и умеренной артериальной гипертонией. Тер архив 2000; 10: 10-3.

17. Palatini P, Parati G. Modulation of 24-h blood pressure profiles: a new target for treatment? J Hypertens 2005; 10: 1799-801.

18. Горбунов В.М., Оганов Р.Г., Деев А.Д. Сравнительная информативностьразличных способов анализа результатов суточного мониторирования артериального давления в оценке эффективности антигипертензивной терапии. Кардиоваск тер профил 2003; 1: 17-25.

19. Voogel AJ, van der Meulen JH, van Montfrans GA. Effects of antihypertensive drugs on the circadian blood pressure profile. J Cardiovasc Pharmacol 1996; 28(3): 463-9.

20. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.

21. Fagard RH, Cornelissen A. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 2007; 25: 2193-8.

22. Dahlof B, Lindholm LM, Carney S, et al. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group. J Hypertens 1997; 15(11): 1327-35.

23. Omvilk P, Thaulow E, Herland OB, et al. Duoble-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens 1993; 11(1): 103-13.

24. Маношкина Е.М., Раздобреева И.И., Кукушкин С.К. Влияние антигипертензивной терапии на психологический статус ликвидаторов последствий аварии на Чернобыльской АЭС. РФК 2006; 1: 4-10.